Pet Scan Ovarian Cancer

Please note that texts older than 2 years are under revision and may not reflect the current scientific status. Positron emission tomography (PET) is a nuclear medical procedure that uses radionuclides to visualize metabolic processes in the body. The background to this is the fact that malignant tumors often have a much more intensive metabolism than benign tissue. For example, radioactively labeled glucose is used, which makes the sugar metabolism of tissues visible.


Source: © dkg-web During the examination, the patient is injected with dextrose containing small amounts of a short-lived emitter (positron emitter). This is usually fluorine-18-deoxyglucose (FDG), which is why the examination is also called FDG-PET. The labeled sugar (“tracer”) accumulates rapidly, especially in tumor tissue, where it is metabolized. The radiation (emission) emitted by the sugar is measured externally via a detector. A computer calculates the radiation values into images on which possible tumor foci – depending on the PET device – clearly stand out as dark or particularly bright spots. Compared to other radioactive substances (see section on scintigraphy), positron emitters have the advantage that they can be precisely localized in the body. This makes it possible to detect tumors that are only a few millimeters in size and could hardly or not at all be found with other methods (e.g., CT, MRI).


PET is a radiation diagnostic procedure, which means that the patient is exposed to radioactive radiation. However, this exposure is relatively low and only of short duration, because low radiation substances are used in very low doses, which have a short decay time, i.e. are quickly neutralized or excreted. Compared to other methods, PET alone has hardly been shown to have any additional benefit. Metabolism also increases in diseases other than cancer, such as inflammation. Therefore, a positive finding in PET cannot be safely assumed to be a malignant tumor. However, by combining PET with computed tomography (PET/CT), the diagnostic value of PET can be improved. (red) Sources: M. Galanski, K. Lackner: Principles of Imaging Diagnostics in Oncology, in: H.-J. Schmoll. K. Höffken, K. Possinger (eds.): Kompendium Internistische Onkologie, Springer Verlag 2005, pp. 429-448 Last content update on: 03.10.2022

Further methods of cancer diagnostics:

Skip navigation

  • X-ray examination
  • Computed tomography (CT)
  • Magnetic resonance imaging (MRI) for cancer
  • Scintigraphy
  • Ultrasound (sonography)
  • Endoscopy (mirror examination)
  • Cell and tissue samples
  • Laboratory tests

This page was automatically translated and accurateness of translation is not guaranteed. Please refer to the English version for a source text.

Benchmarking intra-tumor heterogeneity in ovarian cancer: linking in vivo imaging phenotypes with histology and genomics

Benchmarking intra-tumor heterogeneity in ovarian cancer: linking in vivo imaging phenotypes with histology and genomics

Sponsors Lead Sponsor: Memorial Sloan Kettering Cancer Center
Source Memorial Sloan Kettering Cancer Center
Brief Summary The purpose of this research study is to learn if differences in scans prior to surgery are detectable match differences observed when viewing tumor specimens with pathology and genetic testing. In In this study, we will use magnetic resonance imaging [MRI] and positron emission tomography [PET] scans. There are no intuitive advantages from the advantages of this study.
Overall status Completed
Start date 2014-05-01
Completion date 2020-06-15
Primary completion date 2020-06-15
Phase N / A
Study Type Interventional
Primary outcome
Measure Time window
Genomic markers of spatial heterogeneity 1 year
Secondary outcome
Measure Time window
Histological and immunohistochemical features 1 year
Enrollment 26
  • Ovarian cancer
Intervention Intervention type:Procedure Intervention name: PET/CT Scan Arm group label: MRI with DW-MRI & DCE-MRI & FDG PET/CT Intervention type: Procedure Intervention name: MRI Arm group label: MRI with DW-MRI & DCE-MRI & FDG PET/CT
Eligibility Criteria:Inclusion criteria: – ≥ 18 years of age on the date of signing the informed consent form. – Histologically confirmed or suspected high grade serous stage III or IV ovarian cancer. – Planned to undergo primary debulking surgery. Exclusion criteria: – Pregnant patients – Patients unable to provide valid informed consent due to a general medical or psychiatric condition or physiological status unrelated to the presence of ovarian cancer – Patients unwilling or unable to undergo MRI, including patients with contraindications to MRI such as the presence of pacemakers or incompatible intracranial vascular clamps, claustrophobia, inability to lie flat for the duration of study etc. – Patients with a metallic hip implant or other metallic implant or device in the hip pelvis that could distort the local magnetic field and affect MRI quality. – Radiation therapy to the abdomen or pelvis within 6 months of the screening visit. Subjects with a current diagnosis of epithelial ovarian tumor with low malignant potential (borderline carcinomas) are not eligible – Patients with synchronous primary endometrial cancer or a history of endometrial cancer unless all of the following conditions are met: – Stage no greater than IB – No more than one superficial invasion of the myometrium – No vascular or lymphatic invasion – No poorly differentiated subtypes, including serous, clear cell, or other FIGO grade 3 lesions. – Patients who have received prior chemotherapy for an abdominal or pelvic tumor excluded. Patients who have received debulking prior to their first neoadjuvant chemotherapy are excluded. Patients may have previously received adjuvant chemotherapy breast cancer. – With the exception of non-melanoma skin cancer and other specific malignancies such as z as mentioned above, patients with other invasive malignancies who had (or have) any evidence. of other cancers that have occurred in the past 3 years are excluded. – Unresolved bowel obstruction. – History or current evidence of disease, therapy, or laboratory abnormality that may occur confound the results of the study, affect the patient’s full participation duration of the study. – Absence of target lesions (> 2.0 cm) on staging CT – patients unlikely to be optimally compacted at surgery (tumor implants are difficult to treat). Reach sites [i.e., ligamentum falciforme or porta hepatis], adrenal retroperitoneal lymphadenopathy) Gender: Female Minimum age: 18 years Maximum age: N/A Healthy volunteers: No
Total official
Last name Role Affiliation
Hebert Vargas Alvarez, MD Principal Investigator Memorial Sloan Kettering Cancer Center
Total Contact Contact information is only displayed if the study is recruiting subjects.
Memorial Sloan Kettering West Harrison | Harrison, New York, 10604, United States.
Memorial Sloan Kettering Cancer Center | New York, New York, 10065, United States
Location Countries United States
Review date 2020-06-01
Responsible Party Type:Sponsor
  • MRI
  • Histological heterogeneity
  • 14-061
Has expanded access No
Number of arms 1
Arm group Label:MRI with DW-MRI & DCE-MRI & FDG PET/CT Type: Experimental Description:Study participants will receive 1 scan within the 7 days immediately preceding surgery (PET/CT as a standard of care and MRI as a research study). The MRI and PET/CT scanning procedures are identical to those used in routine clinical examinations of the abdomen and pelvis.
Study Design Info Assignment:N/A Intervention Model: Single Group Assignment Main Purpose: Diagnosing Masking: None (Offense Label)

This information was retrieved directly from the website without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on, this will be updated automatically on our website as well.

  • NCT05113368Not yet recruitedConditions: Ovarian cancer, Serous ovarian cancer.
  • NCT05200364RecruitedConditions: Ovarian cancer, Ovarian cancer, Ovarian cancer, Fallopian tube cancer, Primary peritoneal carcinoma
  • NCT05187208Not yet recruitedConditions: Epithelial ovarian cancer, Ovarian cancer, Stage III ovarian cancer, Stage IV ovarian cancer.
  • NCT04251052RecruitedConditions: Ovarian Cancer
  • NCT04214782Not yet recruitedConditions: Ovarian cancer
  • NCT03831230RecruitmentConditions: Ovarian cancer
  • NCT03704467CompletedConditions: Ovarian cancer
  • NCT03656809CompletedConditions: Ovarian cancer
  • NCT03916679RecruitedConditions: Ovarian cancer
  • NCT03881683CompletedConditions: Ovarian Cancer

PET/CT Scan Clinical Trials

  • NCT00184964Unknown statusConditions: Carcinoma, non-small cell lung
  • NCT03557450CompletedConditions: Normal subjects
  • NCT02572765RecruitedConditions: Hypertension
  • NCT00828126CompletedConditions: Melanoma
  • NCT00686465CompletedConditions: Non-small cell lung cancer, breast cancer, head and neck cancer, ovarian cancer, esophageal cancer, lymphoma
  • NCT00380666RecalledConditions: Non-small cell lung cancer
  • NCT00588328DiscontinuedConditions: Lung Cancer, Non-Hodgkin’s Lymphoma
  • NCT00843219ClosedConditions: Lung Cancer
  • NCT02202317CompletedConditions: Liver Cancer, liver tumors
  • NCT01964625CompletedConditions: Chronic Graft-versus-Host Disease.

Pet Scan Ovarian Cancer.

Leave a comment

Your email address will not be published. Required fields are marked *